Considering the need for new, well tolerated and effective treatments to improve survival in metastatic NSCLC after platinum-based chemotherapy, Tumor Treating Fields (TTFields) therapy represents an innovative option. TTFields are electric fields that exert physical forces on electrically charged cellular components in dividing cancer cells, thus disrupting cell function.

cquired resistance to EGFR tyrosine kinase inhibitors (TKIs), even including the third-generation agent osimertinib, limits duration of response and survival in treated patients with EGFR-mutant lung tumors. A potential strategy to improve outcomes is the concomitant use of EGFR-targeted agents and platinum doublet chemotherapy, although EGFR TKI treatment might attenuate the effect of cytotoxic agents.

The randomized phase III ADAURA study was conducted in response to the unmet need of improving 5-year overall survival (OS) rates in patients with completely resected EGFR-mutated, stage IB-IIIA non-small cell lung cancer (NSCLC), which are estimated to range between 45 % and 85 %. In ADAURA, 682 patients after complete resection of stage IB, II, or IIIA NSCLC with or without adjuvant chemotherapy received either osimertinib 80 mg OD or placebo for 3 years.